Oral leukoplakia: To treat or not to treat

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Oral leukoplakia : To treat or not to treat. / Holmstrup, Palle; Dabelsteen, Erik.

In: Oral Diseases, Vol. 22, No. 6, 20.01.2016, p. 494-497.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Holmstrup, P & Dabelsteen, E 2016, 'Oral leukoplakia: To treat or not to treat', Oral Diseases, vol. 22, no. 6, pp. 494-497. https://doi.org/10.1111/odi.12443

APA

Holmstrup, P., & Dabelsteen, E. (2016). Oral leukoplakia: To treat or not to treat. Oral Diseases, 22(6), 494-497. https://doi.org/10.1111/odi.12443

Vancouver

Holmstrup P, Dabelsteen E. Oral leukoplakia: To treat or not to treat. Oral Diseases. 2016 Jan 20;22(6):494-497. https://doi.org/10.1111/odi.12443

Author

Holmstrup, Palle ; Dabelsteen, Erik. / Oral leukoplakia : To treat or not to treat. In: Oral Diseases. 2016 ; Vol. 22, No. 6. pp. 494-497.

Bibtex

@article{f197dd01640b4dcd894d6acb135efb6b,
title = "Oral leukoplakia: To treat or not to treat",
abstract = "The idea of identifying oral lesions with a precancerous nature, i.e. in the sense of pertaining to a pathologic process with an increased risk for future malignant development, of course is to prevent frank malignancy to occur in the affected area. The most common oral lesion with a precancerous nature is oral leukoplakia, and for decades it has been discussed how to treat these lesions. Various treatment modalities, such as systemic therapies and surgical removal, have been suggested. The systemic therapies tested so far include retinoids, extracts of green tea, inhibitors of cyclooxygenase-2 and of epidermal growth factor, and peroxisome proliferator activated receptor-γ agonists (William, 2012), but there is no generally approved standard systemic therapy regimen so far (William, 2012). This article is protected by copyright. All rights reserved.",
author = "Palle Holmstrup and Erik Dabelsteen",
note = "This article is protected by copyright. All rights reserved.",
year = "2016",
month = jan,
day = "20",
doi = "10.1111/odi.12443",
language = "English",
volume = "22",
pages = "494--497",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Oral leukoplakia

T2 - To treat or not to treat

AU - Holmstrup, Palle

AU - Dabelsteen, Erik

N1 - This article is protected by copyright. All rights reserved.

PY - 2016/1/20

Y1 - 2016/1/20

N2 - The idea of identifying oral lesions with a precancerous nature, i.e. in the sense of pertaining to a pathologic process with an increased risk for future malignant development, of course is to prevent frank malignancy to occur in the affected area. The most common oral lesion with a precancerous nature is oral leukoplakia, and for decades it has been discussed how to treat these lesions. Various treatment modalities, such as systemic therapies and surgical removal, have been suggested. The systemic therapies tested so far include retinoids, extracts of green tea, inhibitors of cyclooxygenase-2 and of epidermal growth factor, and peroxisome proliferator activated receptor-γ agonists (William, 2012), but there is no generally approved standard systemic therapy regimen so far (William, 2012). This article is protected by copyright. All rights reserved.

AB - The idea of identifying oral lesions with a precancerous nature, i.e. in the sense of pertaining to a pathologic process with an increased risk for future malignant development, of course is to prevent frank malignancy to occur in the affected area. The most common oral lesion with a precancerous nature is oral leukoplakia, and for decades it has been discussed how to treat these lesions. Various treatment modalities, such as systemic therapies and surgical removal, have been suggested. The systemic therapies tested so far include retinoids, extracts of green tea, inhibitors of cyclooxygenase-2 and of epidermal growth factor, and peroxisome proliferator activated receptor-γ agonists (William, 2012), but there is no generally approved standard systemic therapy regimen so far (William, 2012). This article is protected by copyright. All rights reserved.

U2 - 10.1111/odi.12443

DO - 10.1111/odi.12443

M3 - Journal article

C2 - 26785709

VL - 22

SP - 494

EP - 497

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 6

ER -

ID: 157242098